Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine A meta-analysis

Background: The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine. Methods: Randomized controlled trials (RCTs) of ubrogepant for treatment of acute migraine were identified in PubMed, MEDLINE, EMBASE, and the Cochrane Library from database establishment to June 2020; we also searched ClinicalTrials.gov manually during the same period. Then, RevMan 5.3 software was used to perform a meta-analysis on each outcome measure. Results: A total of 5 RCTs involving 4903 patients were included; there were 3358 cases in the ubrogepant group and 1545 cases in the placebo group. The meta-analysis showed the following results: at 2 hours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group (odds ratio [OR] = 1.71, 95%CI: 1.48-1.97, P < .00001; OR = 1.33, 95%CI: 1.22-1.45, P < .00001; OR = 1.07, 95%CI: 1.03-1.11, P = .0006; OR = 1.21, 95%CI: 1.14-1.28, P < .00001). The incidence of common adverse events was similar between the 2 groups (P > .05). Conclusion: Ubrogepant is effective and safe for the treatment of acute migraine. Registration number: PROSPERO CRD42019145286.

Automated summary

This study systematically evaluated the efficacy and safety of ubrogepant for acute migraine treatment, finding that ubrogepant group had significantly higher percentages of pain relief and symptom absence at 2 hours postdose compared to the placebo group, with similar incidence rates of common adverse events between the two groups.